Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth…

Capsule:
Adding recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment protocols in adolescent/young adult men with hypogonadotropic hypogonadism results in normal testicular growth and may hasten induction of spermatogenesis.

Authors:
Margaret Zacharin, M.B.B.S., Matthew A. Sabin, Ph.D., Veena V. Nair, M.D., Preeti Dagabdhao, M.D.

Volume 98, Issue 4, Pages 836-842, October 2012

Abstract:

Objective:
To assess effects on spermatogenesis of adding recombinant FSH (rFSH) to HCG treatment protocols for adolescent/young adult males with hypogonadotrophic hypogonadism (HH).

Design:
Observational descriptive study.

Setting:
Outpatient clinics in Australia and India.

Patients:
19 males with Hypogonadotrophic Hypogonadism (age 14.5–31 years).

Interventions:
Treatment with either HCG treatment alone (n=9; Group 1) or in combination with rFSH (n=10; Group 2), over 6-9 months.

Main Outcome Measures:
Combined testicular volume (CTV), and testosterone, Inhibin B, semen/urine analysis at 6 – 9 months.

Results:
There were no differences between groups for baseline variables or changes in CTV with treatment. Despite this, evidence of spermatogenesis was present in all Group 2 patients by 9 months [range 0.2 to 15×10653 /ml] compared with 3/9 patients in Group 1 [range 0 to <1x10654 /ml]; p=0.003. Whole group and subgroup analyses did not demonstrate significant correlations between age at onset of treatment and either CTV or sperm count. Conclusions:
Addition of rFSH to HCG treatment protocols in adolescent/young adult HH males results in normal testicular growth and may hasten induction of spermatogenesis.

Translate »